Aurora Rejects Curaleaf Hostile Bid, Opens Door to Competing Offers

Aurora Board Unanimously Rejects Curaleaf Proposal

Aurora's board of directors unanimously rejected Curaleaf's hostile bid, citing inadequate valuation and insufficient upside for Aurora shareholders. The rejection, announced in a regulatory filing on September 2, marks the first formal response since Curaleaf disclosed its unsolicited approach in mid-August. Aurora didn't disclose the specific dollar terms Curaleaf proposed, but the board statement characterized the offer as "materially undervaluing" Aurora's assets and future cash-flow potential.

The rejection doesn't close the door. Aurora confirmed that its financial advisers — unnamed in the filing — are now evaluating a range of strategic alternatives, including potential competing bids from other MSOs or institutional investors. That language is standard M&A signaling: Aurora's fishing for a better price.

Curaleaf's Bid Structure and Voting-Control Dispute

Curaleaf's proposal included a mix of cash and stock, but Aurora's board flagged concerns over voting control and post-merger governance. According to the rejection statement, Curaleaf's offer would have resulted in Aurora shareholders holding a minority stake in the combined entity, with limited board representation and no guaranteed veto rights over major capital decisions.

Aurora's management argued that the proposed governance structure transferred too much control to Curaleaf's existing equity holders, diluting Aurora's strategic influence. The filing didn't specify the exact cash-to-stock ratio Curaleaf offered. Industry observers note that most cross-border cannabis M&A deals in 2026 have skewed heavily toward stock consideration to preserve acquirer liquidity.

Timeline: From Quiet Approach to Public Standoff

Curaleaf first approached Aurora privately in July 2026, escalating to a public disclosure in mid-August after Aurora declined to engage. Here's the timeline, reconstructed from regulatory filings and press statements:

• July 15, 2026: Curaleaf submits preliminary non-binding proposal to Aurora's board.
• July 28, 2026: Aurora responds with a request for additional financial detail and governance terms.
• August 12, 2026: Curaleaf discloses the approach in a press release, characterizing it as a "compelling opportunity" for Aurora shareholders.
• September 2, 2026: Aurora formally rejects the bid and announces it's evaluating alternatives.

The public disclosure in August was a classic hostile-bid tactic. Curaleaf bypassed Aurora's board and appealed directly to shareholders, hoping retail and institutional holders would pressure management to negotiate.

Strategic Alternatives: What Aurora Is Considering

Aurora's statement that it's "evaluating strategic alternatives" is M&A code for soliciting competing bids or exploring a sale on better terms. The company didn't name potential suitors, but the disclosure signals that Aurora believes it can extract a higher valuation from another buyer or force Curaleaf to sweeten its offer.

Possible alternatives include a competing bid from another U.S. MSO, a private-equity consortium, or a strategic partnership that stops short of a full acquisition. Aurora's advisers are likely running a dual-track process: one path toward a sale, another toward a recapitalization or joint venture that preserves Aurora's independence.

Valuation Gap: Aurora's Cash Flow vs. Curaleaf's Offer

Aurora's rejection hinged on a valuation dispute: the board believes Curaleaf's offer doesn't reflect Aurora's adjusted EBITDA trajectory or its cultivation-efficiency gains. Aurora reported CAD $42 million in adjusted EBITDA for the trailing twelve months ended June 30, 2026. That's a 19% year-over-year increase. Cost reductions and higher-margin medical sales in Germany and Australia drove the growth.

Curaleaf's offer, according to Aurora's statement, applied a multiple that Aurora's advisers deemed "below recent precedent transactions" in the Canadian LP sector. The board didn't cite specific comps, but two Canadian LP acquisitions in 2025 — both involving distressed sellers — traded at 6-8x forward EBITDA. Aurora's rejection implies it believes it deserves a premium to those distressed multiples.

Shareholder Reaction and Proxy Fight Risk

Aurora's largest institutional shareholders haven't publicly commented, but the rejection raises the risk of a proxy fight if Curaleaf decides to escalate. Curaleaf could nominate its own slate of directors at Aurora's next annual meeting, scheduled for December 2026, and campaign for shareholder support to replace Aurora's board with directors willing to negotiate.

That path is expensive and uncertain. Proxy fights in cross-border cannabis M&A are rare because of the regulatory complexity: U.S. MSOs can't directly own Canadian LPs under current federal law, so any deal would require a complex holding-company structure or a regulatory workaround. Curaleaf hasn't indicated whether it intends to pursue a proxy contest.

What Happens Next: Timeline and Market Implications

Aurora's advisers now have 30-60 days to solicit competing bids before the company must either accept a revised offer or commit to remaining independent. If no competing bidder emerges, Aurora faces pressure to justify its rejection to shareholders, especially if its stock underperforms in the interim.

For full background on this story, see the CannIntel topic hub on the Curaleaf-Aurora takeover bid. The next signal: whether another MSO or private-equity firm files a competing bid by mid-October. If not, Curaleaf may return with a higher cash component. Or walk away entirely.